In-home care testing, a trained individual is sent to the patient's doorstep to collect a blood sample, negating the need for the patient to travel to a lab or hospital for the tests. The patient receives the test results electronically. Direct-to-consumer testing is becoming more popular as more patients choose home care testing over laboratory testing, which is a key contributor to the market share expansion. Furthermore, advanced sophisticated procedures have simplified testing and expedited test findings. Therefore, creating sophisticated hemoglobin analyzer equipment is anticipated to accelerate market share throughout the projection period.
Governments investigated the prospect of extending blood testing performed at private facilities. Increase in the global prevalence of chronic diseases such as anemia and diabetes. In addition, anemia and thalassemia patients large number of market companies are concentrating on creating portable and point-of-care hemoglobin analyzers. Further, diabetes patients need to undergo testing regularly, which will boost the hemoglobin analyzer's market share during the forecast period. Moreover, the aging population is fueling the rise in diabetes prevalence. The elderly frequently seek access to homecare settings, including portable medical equipment such as hemoglobin analyzers, thereby propelling the market growth.
However, in the upcoming years, industry growth is expected to be constrained by fierce competition between the existing players and the high price of hemoglobin analyzers. In addition, it is expected that time-consuming and strict regulatory standards for hemoglobin analyzers will restrain the market expansion during the forecast period.
Furthermore, there will be attractive potential for the hemoglobin analyzers market to grow due to the growth of the healthcare sector, which is being driven by both public and private actors, particularly in developing economies. Moreover, increase in personal disposable income, growth in awareness of the benefits of hemoglobin analyzers, unhealthy eating patterns, sedentary lifestyles, and a rise in investments in the creation of cutting-edge & innovative technology all positively impact the market growth rate.
Additionally, businesses' increased emphasis on R&D initiatives and rise in adoption of various business strategies, including mergers & acquisitions, collaborations, and partnerships, are anticipated to boost expansion of the market. For instance, on 9th January, 2023, imaware Inc. and Trinity Biotech announced a strategic agreement that will use imaware's built-to-partner digital health platform and Trinity Biotech's cutting-edge reference laboratory facilities to power at-home and remote testing programs for the digital health industry.
By the third year of their collaboration, imaware and Trinity Biotech aim to have more than 650,000 test kits processed annually by Trinity Biotech at its cutting-edge reference lab facility in New York. They also intend to offer seamless follow-up confirmatory testing for imaware users. The alliance will concentrate on delivering fully integrated private and white-label solutions with industry-leading rapid turnaround and patient-centric ecosystem integration, specifically created for the needs of digital health channel partners.
New product launches to flourish the market
ERBA Diagnostics Mannheim GmbH debuted their most latest hematology analyzers at MedLab Middle East, an international symposium for laboratory management and medicine held between February 4–7, 2019, at the Dubai International Convention and Exhibition Centre, Dubai, UAE. Its latest hematology analyzers, the H 360 and H 560, which were unveiled at MedLab 2019, are designed to boost lab productivity and are geared at small to medium laboratories. Only 9 microliters of blood are required for the freshly developed H 360 3-part differential analyzer to process 60 samples per hour. The H 560 5-part differential analyzer, which can process 60 samples per hour and requires a minimum sample volume of 15 microliters, is particularly helpful in paediatric situations. Both technologies make use of a complex 3D scattergram to help interpret the data.
EKF Diagnostics declared that they have chosen McKesson Medical Surgical Inc. to manufacture their portable, reagent-free hemoglobin analyzer, the "DiaSpect Tm." The deal was finalized when the product received 510(k) clearance from the US FDA in April 2021. The device is an appropriate product offering because it has a wide variety of applications in various healthcare settings and requires little training before use.
For instance, an improved DiaSpect Tm was released by EKF Diagnostics in November 2022. The company's point-of-care (POC) middleware, EKF Link, is now securely connected to the handheld hemoglobin analyzer, providing new functionality, including data management and a computed hematocrit value. The DiaSpect Tm is a globally accessible product with an IVD CE mark, FDA clearance, and registration across several countries.
By product type: Full-automatic hemoglobin analyzers are highly developed hemoglobin analyzer devices offer better analysis, higher precision, and more reliable results. These hemoglobin analyzer devices are simple and entirely customizable to meet your needs. Their reliable and cutting-edge hemoglobin test equipment is built from premium materials, including plastics, metal, and toughened fiber, and comes in various styles. These analyzers are well-liked by consumers because of their effectiveness and minimal to no maintenance requirements. Battery- or electrically-powered hemoglobin test devices are available in semi-automatic and automatic configurations. With these accurate hemoglobin test machines, various clinical trials and tests can be carried out.
By application: A simple, quick, and accurate method for blood glucose self-monitoring. The key to reducing diabetes-related problems is accurate blood glucose tracking through routine monitoring. While utilizing this product, which is simple to use and provides accurate results, few droplets of blood are required. It has Biosensor, which gives no pain and quick results (i.e., 9 seconds).
By end user: Due to factors such as rising rates of chronic lead poisoning and sickle cell disease, hereditary spherocytosis and cytochemistries in the aging population, and the global recognition of the chronic granulomatous disease, the clinic's segment is anticipated to expand during the forecast period.
By region: Due to the rise in the prevalence of various blood-related diseases and the increase in the usage of hematology analyzers in the diagnostic industry, hemoglobin analyzer sales are constantly rising in North America. For instance, three million Americans suffer from anemia, a chronic condition that is more prevalent in women "of childbearing age." 400 newborns are diagnosed with hemophilia every year, according to a estimated data from the Centers for Disease Control and Prevention (CDC). In addition, according to the Leukemia and Lymphoma Society, a blood cancer diagnosis in the U.S. is made every three minutes and 186,400 Americans are anticipated to receive a diagnosis of leukemia, lymphoma, or myeloma in the US in 2021.
Competitive analysis and profiles of the major hemoglobin analyzers market players, such as Erba Diagnostics Mannheim GmbH, Alere Inc., I Sens Inc., Infopia Co Ltd, Roche Holding AG, Trinity Biotech plc, Ceragem Medisys, Convergent Technologies, Drew Scientific, and EKF Diagnostics, are provided in this report. Product launches and acquisitions are the key strategies adopted by the market players. These companies have adopted key strategies such as product launches and acquisitions to improve their product portfolios and stay competitive in the market.
Hemoglobin Analyzers Market Report Highlights
By Product Type
By End User
Key Market Players
Ceragem Medisys, Alere Inc., convergent technologies, ekf diagnostics, Roche Holding AG, erba diagnostics mannheim gmbh, Infopia Co Ltd, I Sens Inc., Drew Scientific, Trinity Biotech plc